Investment Thesis
Enzon Pharmaceuticals is in severe financial distress with negative stockholders' equity of -$2.5M, indicating liabilities exceed assets attributable to shareholders. The company generated only $26K in revenue while burning $3.0M in operating cash flow, demonstrating a non-viable business model with massive operating losses (-$5.3M) and negative net income of -$3.4M. Despite holding $42.6M in cash, the company is consuming capital at an unsustainable rate with no clear path to profitability or revenue growth.
Strengths
- Substantial cash position of $42.6M provides near-term runway
- Excellent liquidity ratios (58.57x current ratio) with minimal short-term obligations
- No long-term debt burden
Risks
- Negative stockholders' equity of -$2.5M indicates balance sheet insolvency
- Virtually no revenue generation ($26K) with massive operating losses (-$5.3M)
- Negative operating cash flow of -$3.0M per period indicates unsustainable cash burn
- Deteriorating net income trend (-$3.4M) with negative net margin of -13,111%
- Zero insider activity in last 90 days suggests lack of confidence from management
Key Metrics to Watch
- Revenue generation and path to positive operating income
- Monthly cash burn rate and runway remaining
- Stockholders equity recovery and balance sheet stabilization
Financial Metrics
Revenue
26.0K
Net Income
-3.4M
EPS (Diluted)
$-0.07
Free Cash Flow
-3.0M
Total Assets
42.8M
Cash
42.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-20,426.9%
Net Margin
-13,111.5%
ROE
N/A
ROA
-8.0%
FCF Margin
-11,576.9%
Balance Sheet & Liquidity
Current Ratio
58.57x
Quick Ratio
58.57x
Debt/Equity
N/A
Debt/Assets
11.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T09:20:10.615203 |
Data as of: 2025-12-31 |
Powered by Claude AI